ArticleBMC global and public health2025
Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER).
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01953458 (Therapeutic Option for Hepatitis B and C), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Option for Hepatitis B and C: a French Cohort
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigrants in Europe are disproportionately affected by hepatitis B virus (HBV) infection, especially those coming from endemic countries. We aimed to determine whether migrant status was associated with all-cause mortality risk in people living with chronic HBV infection integrated into a hospital-based care pathway in France.
methodsWe analysed clinical and socio-behavioural data collected over 8 years of follow-up among patients with chronic HBV infection enrolled in the French prospective multicentre cohort ANRS CO22 HEPATHER. Migrant status was tested as a binary variable (non-migrants versus migrants) and according to three categories (low, moderate, and high) of HBV endemicity in the migrants' region of birth. The association between migrant status and all-cause mortality risk was assessed using a multivariable Cox proportional hazards model. A competing risks analysis was conducted for liver-related and non-liver-related mortality.
resultsOf the 5597 study participants, accounting for 33,222.8 person-years (PY), 68.1% were migrants, mainly from Sub-Saharan Africa and Asia. During follow-up, 247 patients died and the all-cause mortality rate [95% confidence interval (CI)] was 7.4 [6.6-8.4]/1000 PY. Migrants had a lower mortality rate than non-migrants: 4.5 [3.7-5.5]/1000 PY versus 13.5 [11.4-15.8]/1000 PY (p < 0.001), irrespective of migrants' region of birth and time since arrival in France. After adjustment for sex, age, living in poverty, alcohol use, tobacco smoking, diabetes, and HBV disease phase, the all-cause mortality risk was still lower in migrants than in non-migrants (adjusted hazard ratio [95% CI] 0.58 [0.43-0.78], p < 0.001). All three migrant HBV endemicity categories had a lower risk of all-cause and non-liver-related mortality than non-migrants. By contrast, these differences were not significant for liver-related mortality.
conclusionsA lower all-cause, liver-related and non-liver-related mortality risk was found among migrants with chronic HBV infection in France compared to non-migrants. However, after multivariable adjustment, the liver-related mortality risk was similar between migrants and non-migrants, indicating that mortality advantage for migrants is explained by the protective adjustment factors, such as younger age, less advanced liver disease and fewer unhealthy behaviours. In contrast, these factors did not fully explain the observed mortality advantage for both non-liver-related and all-cause mortality.
trial registrationClinicalTrials.gov registry number: NCT01953458.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.